Document is current
Any future updates will be listed below
-
Authors
Sanjurjo, Lucía https://orcid.org/0000-0003-4006-8010
Schulkens, Iris A.
Touarin, Pauline
Heusschen, Roy
Aanhane, Ed
Castricum, Kitty C. M.
De Gruijl, Tanja D.
Nilsson, Ulf J. https://orcid.org/0000-0001-5815-9522
Leffler, Hakon https://orcid.org/0000-0003-4482-8945
Griffioen, Arjan W.
Elantak, Latifa
Koenen, Rory R.
Thijssen, Victor L. J. L. https://orcid.org/0000-0002-6146-1842
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (KWF11040)
- License Information
-
More Information
Article History
Received: 25 February 2021
Accepted: 25 November 2021
First Online: 20 December 2021
Competing interests
: The authors declare the following competing interests: H.L. and U.J.N. are shareholders in Galecto Biotech AB, a company developing galectin inhibitors. The remaining authors declare no competing interests.
